Yuki Niwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuki Niwa has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Keito Adachi
Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
24 shared publications - Kimiyo Tabata
Eisai Co., Ltd., Tsukuba Research Laboratory, Tsukuba, Ibaragi, Japan
24 shared publications - Koichiro Hotta
Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
24 shared publications - Ryoga Ishida
Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
24 shared publications - Taro Semba
Eisai Co., Ltd., Tsukuba-shi, Japan
24 shared publications - Tomomi Ishida
Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd, 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan
24 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e100426
Magnitude and Moderators of Depressive Symptom Improvement in Digital Placebo Arms: Systematic Review and Meta-Analysis
Background: Depressive disorders are one of the most prevalent psychiatric disorders globally and impose considerable individual and societal burdens. Psychotherapy, including cognitive behavioral therapy, is recommended as a first-line treatment especially for mild to moderate depressive disorders. However, face-to-face psychotherapy is often limited by issues of accessibility and cost. Digital therapeutics (DTx)—defined as health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient by the International Organization for Standardization—have gained increasing attention as alternatives for overcoming these hurdles. With advances in digital technology, digital placebos have begun to be used as comparators in the clinical trials of DTx to assess the effects of active interventions accurately. However, the characteristics of clinical trials, the magnitude of digital placebos effects, and their moderators remain poorly understood. Objective: This study aimed to characterize clinical trials using digital placebos in control arms and to assess the magnitude and moderators of Patient Health Questionnaire-9 (PHQ-9) improvement in digital placebo arms. Methods: The blinded randomized controlled trials (RCTs) evaluating PHQ-9 by setting digital placebos as comparators were identified by searching MEDLINE, Scopus, Web of Science, PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and ISRCTN in November 2025. The characteristics of the RCTs and of the digital placebos were reviewed systematically. The meta-analysis including subgroup analyses and meta-regressions were conducted to investigate the magnitude and the moderators of the PHQ-9 improvement in digital placebo arms. Results: A total of 29 papers and 30 trials with 5680 participants were included in this systematic review and meta-analysis. The most common trial design was 2-arm, parallel-group RCTs conducted in a single country, adopting “Replaced” and “Mobile” as the placebo approach and delivery type, respectively. The pooled effect size for all the included trials, representing PHQ-9 changes within control arms, was Hedges g=0.44 (95% CI 0.29-0.59) with high heterogeneity (I2=93.2%, τ²=0.14). Subgroup analyses and univariable regression showed that “Primary psychiatric disorder” group (P=.008) and baseline PHQ-9 score (P<.001) were the independent moderators of the improvement in digital placebo arms. Multivariable regression indicated that these 2 variables are the major contributing factors of the high heterogeneity (I2=82.1%, τ²=0.07, R2=51.5%). Conclusions: Our findings indicate that improvement in digital placebo arms is not negligible and should be incorporated into trial design. The factors identified in this study will be useful when estimating expected improvement in control arms and planning adequately powered future DTx clinical trials, alongside other relevant conceptual and methodological factors that may influence digital placebo effects. Trial Registration: PROSPERO CRD420251118826; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251118826
- 9 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e100426
Open AccessMagnitude and Moderators of Depressive Symptom Improvement in Digital Placebo Arms: Systematic Review and Meta-Analysis
Background: Depressive disorders are one of the most prevalent psychiatric disorders globally and impose considerable individual and societal burdens. Psychotherapy, including cognitive behavioral therapy, is recommended as a first-line treatment especially for mild to moderate depressive disorders. However, face-to-face psychotherapy is often limited by issues of accessibility and cost. Digital therapeutics (DTx)—defined as health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient by the International Organization for Standardization—have gained increasing attention as alternatives for overcoming these hurdles. With advances in digital technology, digital placebos have begun to be used as comparators in the clinical trials of DTx to assess the effects of active interventions accurately. However, the characteristics of clinical trials, the magnitude of digital placebos effects, and their moderators remain poorly understood. Objective: This study aimed to characterize clinical trials using digital placebos in control arms and to assess the magnitude and moderators of Patient Health Questionnaire-9 (PHQ-9) improvement in digital placebo arms. Methods: The blinded randomized controlled trials (RCTs) evaluating PHQ-9 by setting digital placebos as comparators were identified by searching MEDLINE, Scopus, Web of Science, PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and ISRCTN in November 2025. The characteristics of the RCTs and of the digital placebos were reviewed systematically. The meta-analysis including subgroup analyses and meta-regressions were conducted to investigate the magnitude and the moderators of the PHQ-9 improvement in digital placebo arms. Results: A total of 29 papers and 30 trials with 5680 participants were included in this systematic review and meta-analysis. The most common trial design was 2-arm, parallel-group RCTs conducted in a single country, adopting “Replaced” and “Mobile” as the placebo approach and delivery type, respectively. The pooled effect size for all the included trials, representing PHQ-9 changes within control arms, was Hedges g=0.44 (95% CI 0.29-0.59) with high heterogeneity (I2=93.2%, τ²=0.14). Subgroup analyses and univariable regression showed that “Primary psychiatric disorder” group (P=.008) and baseline PHQ-9 score (P<.001) were the independent moderators of the improvement in digital placebo arms. Multivariable regression indicated that these 2 variables are the major contributing factors of the high heterogeneity (I2=82.1%, τ²=0.07, R2=51.5%). Conclusions: Our findings indicate that improvement in digital placebo arms is not negligible and should be incorporated into trial design. The factors identified in this study will be useful when estimating expected improvement in control arms and planning adequately powered future DTx clinical trials, alongside other relevant conceptual and methodological factors that may influence digital placebo effects. Trial Registration: PROSPERO CRD420251118826; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251118826
- Open Access
Use of tight junction binders to analyze the barrier function of human placental JEG-3 cells
- 28 May 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (9) , 723-738
Targeting claudins in cancer
Epithelial-derived malignancies account for the majority of human tumours and present considerable treatment challenges owing to their heterogeneity, metastatic potential and resistance to therapy. The claudin family of tetra-transmembrane proteins was identified approximately 28 years ago as containing key regulators of epithelial function. These proteins are integral components of tight junctions, which control barrier integrity, selective channel permeability and cellular organization in epithelial tissues. Subsequent murine studies revealed that claudins also have tissue-specific physiological roles, whereas clinical studies demonstrated that their expression is frequently dysregulated in various cancers, highlighting their potential as therapeutic targets. In the past few decades, increasing efforts to exploit claudins in cancer therapy have led to the development of targeted molecules, including zolbetuximab, a first-in-class CLDN-18.2-targeted antibody for the treatment of gastric cancer, which has been recently approved by the United States Food and Drug Administration. This milestone emphasizes the therapeutic potential of targeting this protein family and its possible role in expanding treatment options for cancer. In this review, we discuss the evolving landscape of claudin-targeting therapeutics, examining key advances, emerging challenges and future prospects.
- 28 May 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (9) , 723-738
Targeting claudins in cancer
Epithelial-derived malignancies account for the majority of human tumours and present considerable treatment challenges owing to their heterogeneity, metastatic potential and resistance to therapy. The claudin family of tetra-transmembrane proteins was identified approximately 28 years ago as containing key regulators of epithelial function. These proteins are integral components of tight junctions, which control barrier integrity, selective channel permeability and cellular organization in epithelial tissues. Subsequent murine studies revealed that claudins also have tissue-specific physiological roles, whereas clinical studies demonstrated that their expression is frequently dysregulated in various cancers, highlighting their potential as therapeutic targets. In the past few decades, increasing efforts to exploit claudins in cancer therapy have led to the development of targeted molecules, including zolbetuximab, a first-in-class CLDN-18.2-targeted antibody for the treatment of gastric cancer, which has been recently approved by the United States Food and Drug Administration. This milestone emphasizes the therapeutic potential of targeting this protein family and its possible role in expanding treatment options for cancer. In this review, we discuss the evolving landscape of claudin-targeting therapeutics, examining key advances, emerging challenges and future prospects.
- Open Access
- 5 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Magnitude and Moderators of Digital Placebo Effects on Depressive Symptoms: Systematic Review and Meta-analysis (Preprint)
BACKGROUND Depressive disorders are one of the most prevalent psychiatric disorders globally and impose considerable individual and societal burdens. Psychotherapy, including cognitive behavioral therapy, is recommended as a first-line treatment especially for mild to moderate depressive disorders. However, face-to-face psychotherapy is often limited by issues of accessibility and cost. Digital therapeutics (DTx) have gained increasing attention as alternatives for overcoming these hurdles. With advances in digital technology, digital placebos have been increasingly adopted as comparators in the clinical trials for DTx. However, the characteristics of the clinical trials, the magnitude of digital placebos and their moderators remain poorly understood. OBJECTIVE The objectives of this study were to investigate the characteristics of clinical trials using digital placebos as comparators, and to assess the magnitude of the digital placebo effects and their moderators on depressive symptoms measured by Patient Health Questionnaire-9 (PHQ-9). METHODS The blind randomized clinical trials (RCTs) evaluating PHQ-9 by setting digital placebos as comparators were identified by searching MEDLINE, Scopus, Web of Science, PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, ISRCTN in November 2025. The characteristics of the RCTs and of the digital placebos were reviewed systematically. The meta-analysis including sub-group analyses and meta-regressions were conducted to investigate the magnitude and the moderators of the digital placebos. RESULTS 29 articles and 30 studies with 5680 participants were included in this systematic review and meta-analysis. The most common trial design was 2-arm, parallel-group study conducted in a single country, adopting “Replaced” and “Mobile” as the placebo approach and delivery type, respectively. The pooled effect size for all the included studies was Hedges’ g = 0.44 (95% CI 0.29 to 0.59) with an overall I2 = 93.2 %. Subgroup analyses showed moderate-to-large and statistically significant placebo effect in the group of primary psychiatric disorders (Hedges’ g = 0.69; 95% CI 0.40 to 0.99). Meta-regressions indicated that the group of primary psychiatric disorders and baseline PHQ-9 score were the independent moderators of the digital placebo effects and the major contributing factors of the high heterogeneity (R2 = 51.5%). CONCLUSIONS Statistically significant digital placebo effects were observed on depressive symptoms, and target population and baseline PHQ-9 score were identified as the independent moderators. These findings would have implications for the planning of future DTx clinical trials using digital placebos for depressive symptoms.
- 5 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMagnitude and Moderators of Digital Placebo Effects on Depressive Symptoms: Systematic Review and Meta-analysis (Preprint)
BACKGROUND Depressive disorders are one of the most prevalent psychiatric disorders globally and impose considerable individual and societal burdens. Psychotherapy, including cognitive behavioral therapy, is recommended as a first-line treatment especially for mild to moderate depressive disorders. However, face-to-face psychotherapy is often limited by issues of accessibility and cost. Digital therapeutics (DTx) have gained increasing attention as alternatives for overcoming these hurdles. With advances in digital technology, digital placebos have been increasingly adopted as comparators in the clinical trials for DTx. However, the characteristics of the clinical trials, the magnitude of digital placebos and their moderators remain poorly understood. OBJECTIVE The objectives of this study were to investigate the characteristics of clinical trials using digital placebos as comparators, and to assess the magnitude of the digital placebo effects and their moderators on depressive symptoms measured by Patient Health Questionnaire-9 (PHQ-9). METHODS The blind randomized clinical trials (RCTs) evaluating PHQ-9 by setting digital placebos as comparators were identified by searching MEDLINE, Scopus, Web of Science, PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, ISRCTN in November 2025. The characteristics of the RCTs and of the digital placebos were reviewed systematically. The meta-analysis including sub-group analyses and meta-regressions were conducted to investigate the magnitude and the moderators of the digital placebos. RESULTS 29 articles and 30 studies with 5680 participants were included in this systematic review and meta-analysis. The most common trial design was 2-arm, parallel-group study conducted in a single country, adopting “Replaced” and “Mobile” as the placebo approach and delivery type, respectively. The pooled effect size for all the included studies was Hedges’ g = 0.44 (95% CI 0.29 to 0.59) with an overall I2 = 93.2 %. Subgroup analyses showed moderate-to-large and statistically significant placebo effect in the group of primary psychiatric disorders (Hedges’ g = 0.69; 95% CI 0.40 to 0.99). Meta-regressions indicated that the group of primary psychiatric disorders and baseline PHQ-9 score were the independent moderators of the digital placebo effects and the major contributing factors of the high heterogeneity (R2 = 51.5%). CONCLUSIONS Statistically significant digital placebo effects were observed on depressive symptoms, and target population and baseline PHQ-9 score were identified as the independent moderators. These findings would have implications for the planning of future DTx clinical trials using digital placebos for depressive symptoms.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Fig S1 shows isotype control has no antitumor activity. Fig S2 shows gating strategy for flow cytometric analysis of TILs. Fig S3 shows induction of ICAM-1 by eribulin. Fig S4 shows establishment of P-gp KO cell lines and ICD activity of eribulin. Fig S5 shows dose-dependent antitumor activity of eribulin-LF + anti-PD-1 Ab. Fig S6 shows PK analysis of eribulin and eribulin-LF in plasma and tumor. Fig S7 shows immunomodulatory activity of eribulin in different 3 regimens. Fig S8 shows TIL population changes not included in the main figures. Fig S9 shows activation of IFN signature by eribulin-LF.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Fig S1 shows isotype control has no antitumor activity. Fig S2 shows gating strategy for flow cytometric analysis of TILs. Fig S3 shows induction of ICAM-1 by eribulin. Fig S4 shows establishment of P-gp KO cell lines and ICD activity of eribulin. Fig S5 shows dose-dependent antitumor activity of eribulin-LF + anti-PD-1 Ab. Fig S6 shows PK analysis of eribulin and eribulin-LF in plasma and tumor. Fig S7 shows immunomodulatory activity of eribulin in different 3 regimens. Fig S8 shows TIL population changes not included in the main figures. Fig S9 shows activation of IFN signature by eribulin-LF.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Legends for supplementary figures S1-S9
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Legends for supplementary figures S1-S9
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Supplementary Materials and Methods not included in the main manuscript
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Supplementary Materials and Methods not included in the main manuscript
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1-S3 from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Antibody lists used in the flow cytometric analysis
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-S3 from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Antibody lists used in the flow cytometric analysis
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Eribulin is a microtubule dynamics inhibitor with tumor microenvironment modulation activity such as vascular remodeling activity. Here, we investigated antitumor and immunomodulatory activities of eribulin and its liposomal formulation (eribulin-LF) as monotherapies or in combination with anti–programmed death 1 (PD-1) Ab. The antitumor activity of eribulin or eribulin-LF as monotherapy or in combination with anti–PD-1 Ab was examined in a P-glycoprotein–knockout 4T1 model. Eribulin and eribulin-LF showed stronger antitumor activity in immunocompetent mice compared with immunodeficient mice, indicating that they have immunomodulatory activity that underlies its antitumor activity. Combination therapy of eribulin and eribulin-LF with anti–PD-1 Ab showed antitumor activity, and the combination activity of eribulin-LF with anti–PD-1 Ab was observed at a lower dose and longer interval of administration compared with that using eribulin. To examine the immunomodulatory activity of eribulin and eribulin-LF and its underlying mechanisms, we performed flow cytometry, IHC, and gene expression profiling. IHC and flow cytometry revealed that eribulin-LF increased microvessel density and intratumoral populations of cytotoxic T cells and natural killer cells rather than eribulin. Gene expression profiling demonstrated that eribulin-LF induces IFNγ signaling. Furthermore, IHC also showed that eribulin-LF increased infiltration of CD8-positive cells together with increased CD31-positive cells. Eribulin-LF also increased ICAM-1 expression, which is essential for lymphocyte adhesion to vascular endothelial cells. In conclusion, eribulin showed combination antitumor activity with anti–PD-1 Ab via immunomodulation due to its vascular remodeling activity, and the liposomal formulation showed improved antitumor activity over the standard formulation.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Eribulin is a microtubule dynamics inhibitor with tumor microenvironment modulation activity such as vascular remodeling activity. Here, we investigated antitumor and immunomodulatory activities of eribulin and its liposomal formulation (eribulin-LF) as monotherapies or in combination with anti–programmed death 1 (PD-1) Ab. The antitumor activity of eribulin or eribulin-LF as monotherapy or in combination with anti–PD-1 Ab was examined in a P-glycoprotein–knockout 4T1 model. Eribulin and eribulin-LF showed stronger antitumor activity in immunocompetent mice compared with immunodeficient mice, indicating that they have immunomodulatory activity that underlies its antitumor activity. Combination therapy of eribulin and eribulin-LF with anti–PD-1 Ab showed antitumor activity, and the combination activity of eribulin-LF with anti–PD-1 Ab was observed at a lower dose and longer interval of administration compared with that using eribulin. To examine the immunomodulatory activity of eribulin and eribulin-LF and its underlying mechanisms, we performed flow cytometry, IHC, and gene expression profiling. IHC and flow cytometry revealed that eribulin-LF increased microvessel density and intratumoral populations of cytotoxic T cells and natural killer cells rather than eribulin. Gene expression profiling demonstrated that eribulin-LF induces IFNγ signaling. Furthermore, IHC also showed that eribulin-LF increased infiltration of CD8-positive cells together with increased CD31-positive cells. Eribulin-LF also increased ICAM-1 expression, which is essential for lymphocyte adhesion to vascular endothelial cells. In conclusion, eribulin showed combination antitumor activity with anti–PD-1 Ab via immunomodulation due to its vascular remodeling activity, and the liposomal formulation showed improved antitumor activity over the standard formulation.
- Open Access
- 18 August 2023
- Published by Wiley in The FEBS Journal
- Vol. 290 (22) , 5373-5394
Biogenesis of fibrils requires C‐mannosylation of PMEL
Premelanosome protein (PMEL), a melanocyte‐specific glycoprotein, has an essential role in melanosome maturation, assembling amyloid fibrils for melanin deposition. PMEL undergoes several post‐translational modifications, including N‐ and O‐glycosylations, which are associated with proper melanosome development. C‐mannosylation is a rare type of protein glycosylation at a tryptophan residue that might regulate the secretion and localization of proteins. PMEL has one putative C‐mannosylation site in its core amyloid fragment (CAF); however, there is no report focusing on C‐mannosylation of PMEL. To investigate this, we expressed recombinant PMEL in SK‐MEL‐28 human melanoma cells and purified the protein. Mass spectrometry analyses demonstrated that human PMEL is C‐mannosylated at multiple tryptophan residues in its CAF and N‐terminal fragment (NTF). In addition to the W153 or W156 residue (CAF), which lies in the consensus sequence for C‐mannosylation, the W104 residue (NTF) was C‐mannosylated without the consensus sequence. To determine the effects of the modifications, we deleted the PMEL gene by using CRISPR/Cas9 technology and re‐expressed wild‐type or C‐mannosylation‐defective mutants of PMEL, in which the C‐mannosylated tryptophan was replaced with a phenylalanine residue (WF mutation), in SK‐MEL‐28 cells. Importantly, fibril‐containing melanosomes were significantly decreased in W104F mutant PMEL‐re‐expressing cells compared with wild‐type PMEL, observed using transmission electron microscopy. Furthermore, western blot and immunofluorescence analysis suggested that the W104F mutation may cause mild endoplasmic reticulumretention, possibly associated with early misfolding, and lysosomal misaggregation, thus reducing functional fibril formation. Our results demonstrate that C‐mannosylation of PMEL is required for proper melanosome development by regulating PMEL‐derived fibril formation.
- 18 August 2023
- Published by Wiley in The FEBS Journal
- Vol. 290 (22) , 5373-5394
Open AccessBiogenesis of fibrils requires C‐mannosylation of PMEL
Premelanosome protein (PMEL), a melanocyte‐specific glycoprotein, has an essential role in melanosome maturation, assembling amyloid fibrils for melanin deposition. PMEL undergoes several post‐translational modifications, including N‐ and O‐glycosylations, which are associated with proper melanosome development. C‐mannosylation is a rare type of protein glycosylation at a tryptophan residue that might regulate the secretion and localization of proteins. PMEL has one putative C‐mannosylation site in its core amyloid fragment (CAF); however, there is no report focusing on C‐mannosylation of PMEL. To investigate this, we expressed recombinant PMEL in SK‐MEL‐28 human melanoma cells and purified the protein. Mass spectrometry analyses demonstrated that human PMEL is C‐mannosylated at multiple tryptophan residues in its CAF and N‐terminal fragment (NTF). In addition to the W153 or W156 residue (CAF), which lies in the consensus sequence for C‐mannosylation, the W104 residue (NTF) was C‐mannosylated without the consensus sequence. To determine the effects of the modifications, we deleted the PMEL gene by using CRISPR/Cas9 technology and re‐expressed wild‐type or C‐mannosylation‐defective mutants of PMEL, in which the C‐mannosylated tryptophan was replaced with a phenylalanine residue (WF mutation), in SK‐MEL‐28 cells. Importantly, fibril‐containing melanosomes were significantly decreased in W104F mutant PMEL‐re‐expressing cells compared with wild‐type PMEL, observed using transmission electron microscopy. Furthermore, western blot and immunofluorescence analysis suggested that the W104F mutation may cause mild endoplasmic reticulumretention, possibly associated with early misfolding, and lysosomal misaggregation, thus reducing functional fibril formation. Our results demonstrate that C‐mannosylation of PMEL is required for proper melanosome development by regulating PMEL‐derived fibril formation.